Teva Nabs FDA Approval For Childhood Allergy Nasal Spray

December 21, 2014 | The US Food and Drug Administration has approved the 40 mcg version of Teva Pharmaceutical Industry‘s QNASL spray. The QNASL spray has been approved for the treatment of nasal symptoms associated with allergic rhinitis, or allergies that include symptoms of hay fever, in children aged 4-11. QNASL 40 mcg is a lower dose than the QNASL Nasal Aerosol, 80 mcg, for adults and adolescents age 12 and over, approved by the FDA in 2012. The QNASL 40 mcg version will reportedly be available by prescription by February 2015. “The approval of QNASL for use in children aged 4-11 is an important advancement for an often difficult-to-treat patient group,” said Dr. Todd Mahr, MD, Director of Pediatric Allergy and Immunology at Gundersen Lutheran Medical Center in La Crosse, Wisconsin. Teva Pharmaceutical Industries was founded in 1901 and since has become one of the leading pharmaceutical companies in the world.